Sun Pharmaceutical Industries (Sun Pharma) saw its share price rise by 12% over four trading days, reaching ₹1,807.80 on the National Stock Exchange (NSE). This increase comes after the company announced a definitive agreement to acquire Organon, a global healthcare company, for $11.75 billion. The acquisition is expected to significantly boost Sun Pharma's revenue, potentially doubling it to around $12 billion. Analysts have varying opinions on the acquisition; while some, like Elara Capital, maintain a 'BUY' rating with a target price of ₹1,968, others, such as ICICI Securities, downgraded their rating to 'HOLD' with a target of ₹1,960. Despite concerns about the $9.5 billion debt raise, analysts believe that the strategic benefits of the acquisition will outweigh the risks, particularly in the women's health and biosimilars markets, which face less competition than traditional generics. The deal is expected to enhance Sun Pharma's market presence, particularly in China and South Korea, while reducing its dependence on the US market.